What is Instil Bio Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Instil Bio's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.75.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Instil Bio could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Instil Bio's Cash-to-Debt or its related term are showing as below:
TIL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.75 Med: No Debt Max: No Debt
Current: 1.75
During the past 5 years, Instil Bio's highest Cash to Debt Ratio was No Debt. The lowest was 1.75. And the median was No Debt.
Instil Bio Cash-to-Debt Historical Data
The historical data trend for Instil Bio's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Instil Bio Cash-to-Debt Chart
|
Instil Bio Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
No Debt |
No Debt |
No Debt |
3.27 |
1.75 |
|
Instil Bio Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
3.27 |
2.68 |
2.32 |
2.13 |
1.75 |
Competitive Comparison of Instil Bio's Cash-to-Debt
For the Biotechnology subindustry, Instil Bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instil Bio's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Instil Bio's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Instil Bio's Cash-to-Debt falls into.
Instil Bio Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Instil Bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Instil Bio's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instil Bio (Instil Bio) Business Description
Traded in Other Exchanges
N/A
Address
3963 Maple Avenue, Suite 350, Dallas, TX, USA, 75219
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.
Executives
| Timothy L. Moore |
officer: Chief Operating Officer |
C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404 |
| Sumita Ray |
officer: Chief Legal and Admin Officer |
C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
| Nimish P Shah |
director |
7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018 |
| Jack Nielsen |
director, 10 percent owner |
C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
| Vivo Capital Fund Ix, L.p. |
10 percent owner |
192 LYTTON AVENUE, PALO ALTO CA 94301 |
| Mcgaughy R Kent Jr |
director |
500 CRESCENT COURT, SUITE 250, DALLAS TX 75201 |
| Curative Ventures V Llc |
10 percent owner |
3963 MAPLE AVENUE, SUITE 390, DALLAS TX 75219 |
| Bronson Crouch |
director, 10 percent owner, officer: CEO and Chairman |
C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219 |
| Vivo Capital Ix, Llc |
10 percent owner |
192 LYTTON AVENUE, PALO ALTO CA 94301 |
| Sandeep Laumas |
officer: CFO and CBO |
8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
| Neil W Gibson |
director |
C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121 |
| Gwendolyn Binder |
director |
C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
| Zachary Roberts |
officer: Chief Medical Officer |
C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219 |
| George Matcham |
director |
C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219 |
| Vijay Chiruvolu |
officer: Chief Technical Officer |
C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037 |
Instil Bio (Instil Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TIL has been successfully added to your